

Syngene

Ref: Syn/Acts/CS/SE/PR/BSE/NSE

January 4, 2016

Syngene International Limited
SEZ Unit,
Biocon Special Economic Zone
Bommasandra-Jigani Link Road
Bangalore 560 099, India
T 91 80 2808 2808
F 91 80 2808 3189
CIN : U51909KA1993PLC014937

www.syngeneintl.com

To

The BSE Limited,
Floor 25, P J Towers,
Dalal Street,
Mumbai 400 001

The National Stock Exchange of India Limited
Exchange Plaza,
Bandra – Kurla Complex,
Bandra (East),
Mumbai- 400 051

“By Mail”

Dear Sir/Madam,

Subject: Intimation of Press Release


Please find enclosed the press release made by the Company, on the topic:

“Syngene appoints Jonathan Hunt as CEO – Designate”

Request to kindly take this on record.

Thanking You,

Yours faithfully,
For Syngene International Limited,



Mayank Verma
Company Secretary
E: Mayank.verma@syngeneintl.com
M: +91 97399 04949
T: + 91 80 2808 2023

Email to
BSE: corp.relations@bseindia.com
NSE: cm1ist@nse.co.in

PRESS RELEASE**Syngene appoints Jonathan Hunt as CEO-designate**

January 04, 2016, Bengaluru

Syngene International Limited, one of Asia's largest Contract Research Organizations, today announced the appointment of Jonathan Hunt as CEO-designate. Mr Hunt will take charge as CEO post the retirement of current CEO Peter Bains in March 2016. Mr Bains, who has worked closely with Syngene as a Director since 2010 and was appointed as the CEO in February, 2015 will continue as a member of the Syngene Board post his retirement.

Commenting on the new appointment, Kiran Mazumdar Shaw, Managing Director, Syngene International said, "We are extremely delighted to have Jonathan Hunt join the Syngene executive leadership team. After the resounding success of its IPO earlier during the year, Syngene is now at an exciting phase of its journey of transforming from a CRO to a full-fledged CRAMs player. Jonathan has a rich experience in the global biopharmaceutical industry and a proven track record of leading transformational change and delivering growth. We are sure, under his leadership, Syngene will continue to strengthen its position in the global CRAMs market."

Added Peter Bains, CEO, Syngene International, "Syngene, with its differentiated strategy of multi model integrated Discovery, Development and Manufacturing capabilities, its expanding customer base and seasoned management team, is on a strong growth trajectory and very well positioned to continue this momentum. Jonathan's experience in building customer-focused organisations, coupled with his leadership and operational track record, make him the ideal selection for this position and we are delighted to welcome him aboard."

Jonathan said, "I am delighted to be joining Syngene at this exciting point in its journey. Syngene has a compelling business model, a track record of delivering operational excellence to its customers and ambitious plans for continued growth. I look forward to working closely with the Board, senior management team and leading the company to a new phase of growth."

In his new role, Jonathan will be responsible for strengthening Syngene's relations with its existing global customers as well as forging new relationships. He will also steer the company's investments in developing and strengthening its capabilities and capacities to augment Syngene's service offerings. Prior to Syngene, Jonathan had a long standing association with Astrazeneca where he held various leadership positions including President & Director of Astrazeneca, Austria and President & COO, Astrazeneca India. Earlier in his career he worked with Bayer Schering Pharma in various capacities. He holds a BA (Business Studies & Economics) from the University of Sheffield, UK and an MBA from Durham University, UK.

About Syngene

Syngene International Limited, (BSE code: 539268, NSE Id: SYNGENE, ISIN Id: INE398R01022) is one of Asia's largest Contract Research Organizations. It provides discovery and developmental services for new molecular entities across multiple platforms including Small Molecules, Large Molecules, Antibody-Drug Conjugates and Oligonucleotides. These services are aimed towards bringing novel molecules to the market by supporting the R&D efforts of organizations across diverse sectors like pharma, biotechnology, nutrition and animal health. Syngene offers an integrated platform for R&D focussed organizations to optimize their R&D investments and develop their novel molecules with a distinctive cost advantage. In FY2015, Syngene serviced 221 clients including 8 of the top 10 global pharma companies. For more details, visit: www.syngeneintl.com

For further information please reach out to:

Investor Contact	Media Contact
Sweta Pachlangiya ✉: +91 80 2808 5481 ☎: +91 96865 09372 Fax: +91 80 2852 3423 ①: sweta.pachlangiya@syngeneintl.com	Sandeep Nair ✉: +91 80 2808 5476 ☎: +91 88843 67776 Fax: +91 80 2852 3423 ①: sandeep.nair@syngeneintl.com